TY - JOUR
T1 - Refining the 10-Year Prediction of Left Ventricular Systolic Dysfunction in Long-Term Survivors of Childhood Cancer
AU - Leerink, Jan M.
AU - van der Pal, Helena J.H.
AU - Kremer, Leontien C.M.
AU - Feijen, Elizabeth A.M.
AU - Meregalli, Paola G.
AU - Pourier, Milanthy S.
AU - Merkx, Remy
AU - Bellersen, Louise
AU - van Dalen, Elvira C.
AU - Loonen, Jacqueline
AU - Pinto, Yigal M.
AU - Kapusta, Livia
AU - Mavinkurve-Groothuis, Annelies M.C.
AU - Kok, Wouter E.M.
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Background: In childhood cancer survivors (CCS) at risk for heart failure, echocardiographic surveillance recommendations are currently based on anthracyclines and chest-directed radiotherapy dose. Whether the ejection fraction (EF) measured at an initial surveillance echocardiogram can refine these recommendations is unknown. Objectives: The purpose of this study was to assess the added predictive value of EF at >5 years after cancer diagnosis to anthracyclines and chest-directed radiotherapy dose in CCS, for the development of left ventricular dysfunction with an ejection fraction
AB - Background: In childhood cancer survivors (CCS) at risk for heart failure, echocardiographic surveillance recommendations are currently based on anthracyclines and chest-directed radiotherapy dose. Whether the ejection fraction (EF) measured at an initial surveillance echocardiogram can refine these recommendations is unknown. Objectives: The purpose of this study was to assess the added predictive value of EF at >5 years after cancer diagnosis to anthracyclines and chest-directed radiotherapy dose in CCS, for the development of left ventricular dysfunction with an ejection fraction
KW - cardio-oncology
KW - childhood cancer survivors
KW - echocardiography
KW - risk prediction model
KW - surveillance
UR - https://www.mendeley.com/catalogue/12ae3f6c-376a-3e38-9a02-8e8b4a354110/
U2 - 10.1016/j.jaccao.2020.11.013
DO - 10.1016/j.jaccao.2020.11.013
M3 - Article
SN - 2666-0873
VL - 3
SP - 62
EP - 72
JO - JACC: CardioOncology
JF - JACC: CardioOncology
IS - 1
ER -